UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Clinical cancer research, 2021-10, Vol.27 (19), p.5225-5235

2021

Volltextzugriff (PDF)

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Clinical cancer research, 2021-10, Vol.27 (19), p.5225-5235

2021

Volltextzugriff (PDF)

Abstract 4239: Ectopic expression of EWS-FLI1 in human neural crest stem cells induces polycomb genes and maintenance of stemness

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.4239-4239

2010

Volltextzugriff (PDF)

Abstract 5169: The polycomb group protein BMI-1 cooperates with Yes-Associated Protein, YAP, to suppress cell contact inhibition in Ewing sarcoma cells

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.5169-5169

2010

Volltextzugriff (PDF)

Abstract 5730: Targeting the cell cycle with AZD8421, a potent and highly selective CDK2 inhibitor

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.5730-5730

2024

Volltextzugriff (PDF)

Abstract LB-233: Modeling Ewing sarcoma initiation in human neural crest stem cells

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.LB-233-LB-233

2011

Volltextzugriff (PDF)

Abstract LB-A09: EED targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.LB-A09-LB-A09

2019

Volltextzugriff (PDF)

Abstract ND06: First disclosure of AZD8421, a highly selective CDK2 inhibitor to address resistance to CDK4/6 inhibitors in breast and CCNE1-high cancers

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7_Supplement), p.ND06-ND06

2024

Volltextzugriff (PDF)

Abstract PR03: Prmt1 and Prmt1-dependent translation initiation are critical vulnerabilities of osteosarcoma

Cancer research (Chicago, Ill.), 2016-03, Vol.76 (5_Supplement), p.PR03-PR03

2016

Volltextzugriff (PDF)

Abstract SY15-01: Modeling the initiation of Ewing sarcoma in human neural crest stem cells

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.SY15-01-SY15-01

2011

Volltextzugriff (PDF)

Acceptability and appropriateness of a novel parent-staff co-leadership model for childhood obesity prevention in Head Start: a qualitative interview study

BMC public health, 2021-01, Vol.21 (1), p.201-201, Article 201

2021

Volltextzugriff (PDF)

Adverse event (AE) incidence rates with cobimetinib (C) plus vemurafenib (V) treatment: Extended follow-up (f/u) of the phase III coBRIM study

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9533-9533

2016

Volltextzugriff (PDF)

Amination-mediated nano eye-drops with enhanced corneal permeability and effective burst release for acute glaucoma treatment

Chemical engineering journal (Lausanne, Switzerland : 1996), 2023-01, Vol.451, p.138620, Article 138620

2023

Volltextzugriff (PDF)

Application of ion chromatography to the semiconductor industry: I. Measurement of acidic airborne contaminants in cleanrooms

Journal of Chromatography A, 1998-04, Vol.804 (1), p.273-278

1998

Volltextzugriff (PDF)

The association of BMI and outcomes in metastatic melanoma: A retrospective, multicohort analysis of patients treated with targeted therapy, immunotherapy, or chemotherapy

The lancet oncology, 2018-02, Vol.19 (3), p.310-322

2018

Volltextzugriff (PDF)

Association of Participation in the Oncology Care Model With Medicare Payments, Utilization, Care Delivery, and Quality Outcomes

JAMA : the journal of the American Medical Association, 2021-11, Vol.326 (18), p.1829

2021

Volltextzugriff (PDF)

Association of programmed death ligand‐1 (PD‐L1) expression with treatment outcomes in patients with BRAF mutation‐positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib

Pigment cell and melanoma research, 2018-07, Vol.31 (4), p.516-522

2018

Volltextzugriff (PDF)

Author Correction: Citizen science and the United Nations Sustainable Development Goals

Nature sustainability, 2019-11, Vol.2 (11), p.1063-1063

2019

Volltextzugriff (PDF)

Beta Blockade and Clinical Outcomes in Aneurysmal Subarachnoid Hemorrhage

The open neurology journal, 2016-12, Vol.10 (1), p.155-163

2016

Volltextzugriff (PDF)

BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression

Cancer research (Chicago, Ill.), 2008-08, Vol.68 (16), p.6507-6515

2008

Volltextzugriff (PDF)

Cancer Epidemiology

Cancer Risk Assessment, 2010, p.397-418

2010

Volltextzugriff (PDF)

Citizen science and the United Nations Sustainable Development Goals

Nature sustainability, 2019-10, Vol.2 (10), p.922-930

2019

Volltextzugriff (PDF)

Clinical features of cobimetinib (COBI)–associated serous retinopathy (SR) in BRAF -mutated melanoma patients (pts) treated in the coBRIM study

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.9033-9033

2015

Volltextzugriff (PDF)

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

Journal of translational medicine, 2017-06, Vol.15 (1), p.146-9, Article 146

2017

Volltextzugriff (PDF)

Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.1074-1074

2016

Volltextzugriff (PDF)

1 – 25 von 111

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieInternational Journal Of Radiation Oncology, Biology, Physics

ThemaBiological And Medical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(102)
Mit Volltextzugriff
(100)

Publikationsform

Sprache

Englisch
(111)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Abstract 4239: Ectopic expression of EWS-FLI1 in human neural crest stem cells induces polycomb genes and maintenance of stemness

Abstract 5169: The polycomb group protein BMI-1 cooperates with Yes-Associated Protein, YAP, to suppress cell contact inhibition in Ewing sarcoma cells

Abstract 5730: Targeting the cell cycle with AZD8421, a potent and highly selective CDK2 inhibitor

Abstract LB-233: Modeling Ewing sarcoma initiation in human neural crest stem cells

Abstract LB-A09: EED targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex

Abstract ND06: First disclosure of AZD8421, a highly selective CDK2 inhibitor to address resistance to CDK4/6 inhibitors in breast and CCNE1-high cancers

Abstract PR03: Prmt1 and Prmt1-dependent translation initiation are critical vulnerabilities of osteosarcoma

Abstract SY15-01: Modeling the initiation of Ewing sarcoma in human neural crest stem cells

Acceptability and appropriateness of a novel parent-staff co-leadership model for childhood obesity prevention in Head Start: a qualitative interview study

Adverse event (AE) incidence rates with cobimetinib (C) plus vemurafenib (V) treatment: Extended follow-up (f/u) of the phase III coBRIM study

Amination-mediated nano eye-drops with enhanced corneal permeability and effective burst release for acute glaucoma treatment

Application of ion chromatography to the semiconductor industry: I. Measurement of acidic airborne contaminants in cleanrooms

The association of BMI and outcomes in metastatic melanoma: A retrospective, multicohort analysis of patients treated with targeted therapy, immunotherapy, or chemotherapy

Association of Participation in the Oncology Care Model With Medicare Payments, Utilization, Care Delivery, and Quality Outcomes

Association of programmed death ligand‐1 (PD‐L1) expression with treatment outcomes in patients with BRAF mutation‐positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib

Author Correction: Citizen science and the United Nations Sustainable Development Goals

Beta Blockade and Clinical Outcomes in Aneurysmal Subarachnoid Hemorrhage

BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression

Cancer Epidemiology

Citizen science and the United Nations Sustainable Development Goals

Clinical features of cobimetinib (COBI)–associated serous retinopathy (SR) in BRAF -mutated melanoma patients (pts) treated in the coBRIM study

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study

Aktive Filter

Suchergebnisse filtern